Provectus Biopharmaceuticals (PVCT) Net Income towards Common Stockholders (2010 - 2026)
Provectus Biopharmaceuticals (PVCT) posted Net Income towards Common Stockholders of -$982,566 for Q2 2026, compared with -$1.81 million a year earlier.
Powered by 
Analysis
Provectus Biopharmaceuticals (PVCT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Net Income towards Common Stockholders at Provectus Biopharmaceuticals was -$5.27 million; for FY2025, it came in at -$5.43 million.
- In prior years, Provectus Biopharmaceuticals' Net Income towards Common Stockholders was -$4.73 million in FY2024, -$3.1 million in FY2023, -$3.55 million in FY2022 and -$5.54 million in FY2021.
- The Q2 2026 figure stands as the highest quarterly Net Income towards Common Stockholders since Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Provectus Biopharmaceuticals | 21.01 Mn | 19.10 Mn | - | -982,566.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -982,566.00 |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | -1.81 Mn |
| Mar 31, 2025 | -1.14 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -846,848.00 |
| Mar 31, 2024 | -504,042.00 |
| Dec 31, 2023 | -663,413.00 |
| Sep 30, 2023 | -775,839.00 |
| Jun 30, 2023 | -835,062.00 |
| Mar 31, 2023 | -827,454.00 |
| Dec 31, 2022 | -732,653.00 |
| Sep 30, 2022 | -713,267.00 |
| Jun 30, 2022 | -1.08 Mn |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -1.24 Mn |
| Sep 30, 2021 | -1.05 Mn |
| Jun 30, 2021 | -1.58 Mn |
API Access
Provectus Biopharmaceuticals Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=PVCT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "PVCT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=PVCT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();